相关实验视频

Updated: Jan 15, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

建模和优化KRAS和EGFR突变肺癌的组合治疗策略

Lanqi Wu¹, Ruocheng Yu¹, Minghui Yao¹

¹Department of Colorectal Surgery and Oncology of the Second Affiliated Hospital and Centre of Biomedical Systems and Informatics of Zhejiang, University-University of Edinburgh Institute (ZJU-UoE Institute), Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310003, P. R. China.

Journal of bioinformatics and computational biology

|October 13, 2025

概括

计算建模确定了KRAS抑制剂和免疫检查点抑制剂 (ICI) 的组合,作为KRAS突变非小细胞肺癌 (NSCLC) 患者的最佳治疗策略.

科学领域:

在瘤学瘤学.
计算生物学计算生物学
精准医学是一门精准的医学.

背景情况:

非小细胞肺癌 (NSCLC) 的发病率和遗传多样性很高,需要先进的治疗方法.
向疗法 (例如EGFR,KRAS的激酶抑制剂) 和免疫疗法 (免疫检查点抑制剂,ICI) 已经推进了NSCLC的治疗.
药物耐药性和NSCLC的低最佳反应率强调了对新型治疗策略的需求.

研究的目的:

开发一个布尔网络模型来模拟非小细胞肺癌 (NSCLC) 患者对各种治疗的反应.
为了评估结合激酶抑制剂和免疫干预的有效性,在 silico.
根据突变背景确定NSCLC的最佳治疗策略.

主要方法:

开发一个布尔网络模型来模拟NSCLC中的生物过程.
将关键酶突变抑制剂和免疫干预措施纳入模型.
使用定量模型,小鼠研究和临床试验数据 (KRYSTAL-7) 验证模拟结果.

主要成果:

布尔网络和定量模型模拟表明,KRAS抑制剂和ICI的组合是KRAS突变NSCLC的最佳选择.
模拟结果与现有的临床前 (小鼠模型) 和临床 (KRYSTAL-7第二阶段) 数据一致.
这项研究证明了计算建模在改进精密瘤治疗中的潜力.

结论:

计算建模,特别是布尔网络,为优化NSCLC治疗策略提供了宝贵的工具.
结合KRAS抑制和ICI疗法对KRAS突变NSCLC患者显示出前景.
预计进一步的临床验证,如KRYSTAL-7第三期试验,将证实这些发现.

关键词:

布尔网络是一个布尔网络.肺癌是一种肺癌.综合疗法综合疗法免疫疗法免疫疗法有针对性的治疗.

更多相关视频

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...